DexCom, Inc. (DXCM)
| Market Cap | 31.47B |
| Revenue (ttm) | 4.15B |
| Net Income (ttm) | 535.20M |
| Shares Out | 392.11M |
| EPS (ttm) | 1.33 |
| PE Ratio | 60.26 |
| Forward PE | 36.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,371,551 |
| Open | 81.46 |
| Previous Close | 81.62 |
| Day's Range | 80.14 - 81.87 |
| 52-Week Range | 57.52 - 132.26 |
| Beta | 1.43 |
| Analysts | Strong Buy |
| Price Target | 98.11 (+22.26%) |
| Earnings Date | May 1, 2025 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time... [Read more]
Financial Performance
In 2024, DexCom's revenue was $4.03 billion, an increase of 11.34% compared to the previous year's $3.62 billion. Earnings were $576.20 million, an increase of 6.41%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price forecast is $98.11, which is an increase of 22.26% from the latest price.
News
DexCom: Growth Is Reaccelerating But Don't Ignore The Risks
I initially rated DexCom's stock as sell due to competition and GLP-1 threats, but surprising 1Q25 growth prompts an upgrade to hold. DXCM posted better than expected growth figures in 1Q25, establish...
Nasdaq Index: Dexcom, Meta, ON Semi Lead US Stocks Rebound on Trade Optimism
Nasdaq jumps as Dexcom, Palantir, and ON Semi soar. Jobs report beats forecasts, easing inflation fears and driving US stock market optimism.
Dexcom Stock Is Today's Big Winner After Earnings. Why the Medtech Is Soaring.
Dexcom, the maker of glucose monitors for patients with diabetes, reports a strong first quarter.
DexCom, Inc. (DXCM) Q1 2025 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Sean Christensen - VP, Finance & IR Kevin Sayer - Executive Chairman, CEO & President Jereme Sy...
Dexcom beats quarterly sales estimates, reiterates annual forecast
Medical device maker Dexcom beat first-quarter sales estimates helped by strong demand for its continuous glucose monitors (CGMs) used by patients with diabetes.
Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program.
Healthy Returns: What drugmakers are saying about Trump's looming pharmaceutical tariffs
What Johnson & Johnson and Eli Lilly are saying about Trump's pharmaceutical tariffs, and Dexcom scores FDA approval for its glucose monitoring system.
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch
The U.S. Food and Drug Administration approved DexCom, Inc.'s DXCM Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes.
DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance
DexCom says its G7 15 Day system will land on the market in the second half of 2025.
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for peopl...
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will ho...
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems
BURNABY, British Columbia--(BUSINESS WIRE)--The Government of Saskatchewan expands public coverage for Dexcom Continuous Glucose Monitoring Systems.
These 20 worst-performing stocks in the S&P 500 sank 17% or more in March
Stocks turned higher on Monday afternoon to finish March on a positive note. Still, the S&P 500 ended with a 5.8% decline for March, with 69% of component stocks down for the month.
Dexcom Appoints Jon Coleman as Chief Commercial Officer
SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Jon Coleman as Chief Commercial Officer.
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom
NEW YORK--(BUSINESS WIRE)--Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform...
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of ...
History Says Shut Up And Buy: 12 Hyper-Growth Blue Chips To Buy Right Now
Market corrections, like the recent dip, are normal and temporary, with historical data showing average declines of 13-14% since 1950. Long-term investors should stay the course. Corrections often lea...
Dexcom Appoints Renée Galá to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Renée Galá to Board of Directors.
Dexcom receives FDA warning letter for two U.S. manufacturing facilities
Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key manufacturing facilities, sending its shares down near...
DexCom Gets FDA Warning Letter After Inspections of Facilities
DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is working on a written response.
DexCom, Inc. (DXCM) Presents at 46th Annual Raymond James Institutional Investors Brokers Conference (Transcript)
DexCom, Inc. (NASDAQ:DXCM) 46th Annual Raymond James Institutional Investors Conference March 4, 2025 10:25 AM ET Company Participants Jereme Sylvain - Chief Financial Officer Matt Carey - Manager of...
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 46th Annual Raymond James Institutional Investors Conference on Tues...
Quality Key in Volatile Market, NFLX & DXCM Value Plays
Friday's trading session showed weakness is possible in the current market, and Lisa Schreiber says investors need to turn to quality in a time of volatility. Lisa expects the U.S. economy to bolster ...
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
On Thursday, Dexcom, Inc.'s DXCM fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion.